Prediction and assessment of the response of Paget's disease to bisphosphonate treatment

Bone

Volumn 24, Issue 5 SUPPL. 1, 1999, Pages 69S-71S

  Hosking, D J ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID;

ARTICLE; BONE TURNOVER; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PAGET BONE DISEASE; PROGNOSIS; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION;

ALKALINE PHOSPHATASE; BONE RESORPTION; DIPHOSPHONATES; ETIDRONIC ACID; HALF-LIFE; HUMANS; OSTEITIS DEFORMANS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TREATMENT OUTCOME;

EID: 0032903588     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00069-1     Document Type: Article

References (13)

1. Adami, S., Mian, M., Gatti, P., Rossini, M. et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 15:415-417; 1994.
2. Brown, J. P., Kylstra, J. W., Bekker, P. J. et al. Risedronate in Paget's disease: Preliminary results of a multicenter study. Sem Arthrit Rheum 23:272; 1994.
3. Gray, R. E. S., Yate, A. J. P., Preston, C. J. et al. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med 64:755-767; 1987.
4. Gutteridge, D. H., Retallack, R. W., Ward, L. C. et al. Clinical, biochemical, hematologic and radiographic responses in Paget's disease following intravenous pamidronate disodium: A 2 year study. Bone 19:387-394; 1996.
5. Hosking, D. J., Eusebio, R. A., and Chines, A. A. Paget's disease of bone: Reduction of disease activity with oral risedronate. Bone 22:51-55; 1998.
6. Patel, S., Coupland, C. A. C., Stone, M. D., and Hosking, D. J. Comparison of methods of assessing response of Paget's disease to bisphosphonate therapy. Arthr Rheum 38:1506-1512; 1995.
7. Patel, S., Pearson, D., and Hosking, D. J. Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone. Arthr Rheum 38:1506-1512; 1995.
8. Patel, S., Stone, M. D., Coupland, C., and Hosking, D. J. Determinants of remission in Paget's disease. J Bone Miner Res 8:1467-1473; 1993.
9. Reid, I. R., Nicholson, M. D., Weinstein, R. S. et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med 101:341-348; 1996.
10. Roux, C., Gennari, C., Farrerons, J. et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthrit Rheum 38:851-858; 1995.
11. Siris, E. S., Chines, A. A., Altman, R. D. et al. Risedronate in the treatment of Paget's disease: An open label, multicenter study. J Bone Miner Res. In press.
12. Siris, E., Weinstein, R. S., Altman, R. et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metabol 81:961-967; 1996.
13. Stone, M. D., Marshall, D. H., Hosking, D. J. et al. Bisphosphonate space measurement in Paget's disease of bone treated with APD. J Bone Miner Res 7:295; 1992.